Rare Congenital Bleeding Disorders from a Tertiary Haematology Referral Center in Western India

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4519-4519
Author(s):  
Anjali Jaydeep Kelkar ◽  
Shashikant Apte ◽  
Varsha Melinkeri ◽  
Samir Melinkeri ◽  
Ashay Karpe ◽  
...  

Abstract Introduction: Bleeding disorders are present in varying frequency in a given population. We present our data of rare bleeding disorders (excluding Haemophilia & von Willebrand’d disease) since little data about the same is available from developing countries. Many of the rare bleeding disorders are associated with a strong history of consanguinity, the frequency of consanguineous marriages are between 12 –42 %. Materials and Methods: These cases were part of the referral for evaluation of congenital bleeding disorders; some of the cases were diagnosed as part of pre-operative coagulation screen. All the cases were subject to a detailed history encompassing the timing site and frequency of bleed, history of consanguinity, umbilical cord bleed. Lab. evaluation included bleeding time (Ivy’s method), clotting time., in vivo adhesion and clot retraction. Prothrombin and activated partial thromboplastin time with correction studies as and when required, Factor XIII screen with urea solubility test. Complete blood count was done prior to bleeding time and platelet adequacy was confirmed. All blood samples used for coagulation assays were collected in sterile citrate vaccutainers. Further investigations were performed including factor assays depending upon the results of the basic profile. Results: Feb 2000 till August 2008. Total No. of cases studies I from Year 2000 970 Abnormal cases 75 Consanguinity 25 Disorder No. Of Cases Factor V Deficiency 5 Factor VII Deficiency 4 Factor X Deficiency 4 Factor XI Deficiency 1 Factor XII Deficiency 6 Factor XIII Deficiency 8 Combined factor deficiency 4 Factor I deficiency 11 Dysfibrinogenemia 6 Factor II deficiency 1 Glanzmann’s thrombasthenemia 25 Bernard soullier’s syndrome 2 Conclusion: In our institution which caters to a large population in and around city of Pune, Maharashtra Western India, we have detected a good number of patients with rare bleeding disorders. These disorders can be found on a more frequent basis as we have a significant incidence of consanguineous marriages, as our data shows i.e approx. 33%. This report highlights need for extended family search and molecular characterization so as to make antenatal diagnosis amenable for severe bleeding disorders.

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4352-4352 ◽  
Author(s):  
Ayesha N Zia ◽  
Muhammad Fawad Bilal ◽  
Madhvi Rajpurkar ◽  
Meera B. Chitlur ◽  
Michael Callaghan ◽  
...  

Abstract Abstract 4352 Introduction: Accurate assessment of bleeding disorders requires a thorough clinical evaluation and appropriate laboratory testing process. These patients comprise a substantial proportion of consultations carried out by hematologists. The limitations of each screening test, and the heterogeneity of these disorders continue to make the diagnosis cumbersome for the practicing clinician. Plasma clotting times, such as the prothrombin time and activated partial thromboplastin time are the most frequently used screening tests to assess adequacy of hemostasis. Thromboelastography (TEG) lends the ability to assess hemostasis globally while also assessing the effects of platelets, leucocytes and red cells on coagulation. Aims: To determine the utility of TEG as an effective screening test for bleeding disorders Methods: Medical records of patients referred to Hematology Service from August 2006 through July 2011 were retrospectively reviewed after institutional review board approval. Results: One hundred ninety-five patients (125 females, 70 males: ages 0.1 to 20 years) were evaluated for a bleeding disorder based on either bleeding symptoms or abnormal routine clotting tests and had TEG performed with low dose tissue factor (1:190 000 concentration). Most common symptoms were epistaxis (83/195), bruising (67/195), menorrhagia (48/195), surgical bleeding (16/195). Twenty-nine patients were diagnosed with a bleeding disorder based on clinical evaluation and laboratory testing. Type 1 vonWillebrand disease (vWD) was diagnosed in 16 patients, heterozygous factor VII deficiency in 6 patients, factor XII deficiency in 3 patients, factor XI deficiency in 2 patients and platelet delta storage pool disease in 1 patient. One patient was a symptomatic hemophilia carrier. Preliminary analysis revealed that among the vWD patients, only 1 patient demonstrated abnormalities in all parameters of TEG [Prolonged Reaction time (R Time), k time (rate of clot formation) and decreased Maximum amplitude (MA)] and 2 showed prolonged R and k time without concomitant decrease in MA. In patients with heterozygous factor VII deficiency, only 2 of 4 patients showed prolonged R and k times. The symptomatic hemophilia carrier, 1 of 3 with factor XII and 1 of 2 patients with factor XI deficiency had prolonged R as their sole abnormality. TEG was completely normal in the patient with platelet delta storage pool disease. The sensitivity of the R time to diagnose a clotting factor (including low factor VIII with vWD) deficiency was only 58% with a specificity of 78%. R time correlated with PTT and PT in up to 50% (vWD: 12%, FVII deficiency: 33%, FXII: 33%, FXI: 50%) of the patients. R time was also prolonged in 46/166 (28%) patients without a definitive bleeding disorder, however 10 of these patients had a lupus anticoagulant. Conclusion: In our study of 195 patients referred for evaluation of bleeding symptoms or abnormal coagulation tests, TEG was of limited value in identifying congenital coagulation defects with both poor sensitivity and specificity. Future studies could examine different agonists or conditions for TEG that may improve its sensitivity for detection of congenital bleeding disorders. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4660-4660
Author(s):  
Ghasem Janbabaei ◽  
Samaneh Borhani ◽  
Masoumeh Rashidi ◽  
Touraj Farazmandfar ◽  
Ramin Shekarriz ◽  
...  

Abstract Abstract 4660 Objectives: Menorrhagia is a common presentation of bleeding disorders, especially VWD in women. We decided to determine the frequency of these disorders in women with menstruation problems. Materials and Methods: 208 patients in reproductive age with menorrhagia were investigated for bleeding disorders in two steps. Step one includes CBC, PT, PTT and BT, which performed for all patients, and for patients who had an abnormality in step one, step two was considered. Step two includes VWAg, RCO, factors level, RIPA and platelet aggregometry. Results: Among 208 patients who investigated for bleeding disorders 53 patients (25%) had abnormalities in coagulation tests or platelet count. In our survey frequencies of bleeding disorder was VWD=14(6.73%), thrombocytopenia=13(6.25%), deficiency of factor II= 2(0.96%), factor V=1(0.48%), factor VII=3(1.44%), factor VIII=2(0.96%), Factor XI =4(1.92%), factor XII=4(1.92%), Bernard Soulier=2(0.96%). Furthermore, we found 18 patients (8.65%) who had abnormal PT, PTT or BT with no definite diagnosis. Conclusion: In this study, the most common bleeding disorder was VWD and thrombocytopenia ranked second disorders. Although other bleeding disorders are rare, in our study a number of them were found. So, we recomment the above coagulation test for women with menorrhagia. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3379-3379
Author(s):  
Trishala Agrawal ◽  
Louisa Mazza-Hilway ◽  
Alice J. Cohen ◽  
Sari H Jacoby

Abstract Abstract 3379 Background: The literature in the past has recommended pre-operative (PRE-O) coagulation screening only when indicated by history or physical exam. Despite these recommendations, surgeons continue to order PT and PTT prior to surgery, especially in children, because they have often not been hemostatically challenged. We evaluated the usefulness of screening tests in identifying significant bleeding risk and associated cost. Methods: We performed a retrospective audit on children referred to the hemophilia center sent for further evaluation of abnormal PT and PTT on PRE-O screening. We reviewed 62 patients who had 80 procedures, out of which 70 procedures were evaluable with complete data. Age, personal and family history of bleeding, coagulation tests, PRE-O and post-operative (PO) treatment, and immediate PO bleeding were assessed. Results: The most common procedure that led to PRE-O screening was tonsillectomy/adenoidectomy at 61% (49/80). Other procedures included orthopedic, GI, oral, dental extractions, and myringotomies. Only 2.5% (2/80) were cardiac procedures. The mean patient age was 6 years (range 1–16). 55% (34/62) had no personal or family history of bleeding. 22.5% (14/62) had a family history of mild bleeding such as epistaxis or menorrhagia. 8% (5/62) had a family history of major bleeding disorders such as Von Willebrand disease (VWD) or hemophilia. 14.5% (9/62) had a personal history of bleeding, mild or major. The most common abnormal screening test was the PT at 40% (25/62). 27% (17/62) had an abnormal PTT (3.2% \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(262\) \end{document} with a significantly abnormal PTT above 50). 22.5% (14/62) were referred for abnormal PT/PTT. 8% (5/62) with an abnormal PT and/or PTT corrected on repeat studies. The remaining 9.6% (6/62) were referred for other reasons such as positive family or personal history and a high risk procedure. Additional coagulation tests ordered because of prolonged PT or PTT varied and included additional factor assays (Table 1). The mean cost of additional testing was >$1000. Factor VII was the most common factor deficiency identified with a mean activity of 47% (27–54%) (normal 55–163%) followed by factor XII deficiency with a mean activity of 39% ( 19–49%) (normal 46–168%). PRE-O, 5 patients received support with either Humate P, Stimate, Amicar, or DDAVP, 4 with a diagnosis of VWD and 1 with Jacobsen Syndrome; 3 of these patients received PO Amicar. PO, 69/70 procedures were completed with minimal (2–45 mL) bleeding. Only 1/70 procedures had significant PO bleeding, despite normal tests. This patient did not have any significant immediate PO bleeding, but had delayed bleeding reported at day 7 requiring cauterization. No other cases of delayed PO bleeding were reported to our clinic. Conclusion: In patients who undergo routine screening by laboratory testing only, the most common abnormality found was a prolonged PT. Subsequent workup of patients with abnormal screening tests identified factor VII or factor XII deficiencies most frequently. Only one patient with abnormal PT/PTT was diagnosed with a significant bleeding disorder, VWD. Major bleeding occurred rarely. This study demonstrates that the cost of extensive PRE-O coagulation testing is high with minimal clinical impact. Disclosures: No relevant conflicts of interest to declare.


1984 ◽  
Vol 51 (03) ◽  
pp. 331-333 ◽  
Author(s):  
Abdalla S Awidi

SummaryThe results of a three year prospective study of inherited bleeding syndromes in Jordan is presented. There were 112 patients from 64 families. Of these there were 42 patients with hemophilia A, 23 with Glanzmann’s thrombasthenia, 22 with von Willebrand’s disease, 11 with Christmas disease, 6 with hypofibrinogenemia, 3 with afibrinogenemia, 2 with factor XIII deficiency, 2 with storage pool disease and 1 with factor XI deficiency. The pattern of inherited bleeding syndromes in Jordan is different from that seen in Europe and U.S.A. in that Glanzmann’s thrombasthenia is very common. High proportion of hemophiliacs were severe. Arthropathy was common. A significant number of bleeders had fatal hemorrhage. In a high proportion of patients, no family history of bleeding was found.


Blood ◽  
1990 ◽  
Vol 76 (4) ◽  
pp. 731-736 ◽  
Author(s):  
KA Bauer ◽  
BL Kass ◽  
H ten Cate ◽  
JJ Hawiger ◽  
RD Rosenberg

Abstract Despite significant progress in elucidating the biochemistry of the hemostatic mechanism, the process of blood coagulation in vivo remains poorly understood. Factor IX is a vitamin K-dependent glycoprotein that can be activated by factor XIa or the factor VII-tissue factor complex in vitro. To investigate the role of these two pathways in factor IX activation in humans, we have developed a sensitive procedure for quantifying the peptide that is liberated with the generation of factor IXa. The antibody population used for the immunoassay was raised in rabbits and chromatographed on a factor IX-agarose immunoadsorbent to obtain antibody populations with minimal intrinsic reactivity toward factor IX. We determined that the mean level of the factor IX activation peptide (FIXP) in normal individuals under the age of 40 years was 203 pmol/L and that levels increased significantly with advancing age. The mean concentration of FIXP was markedly reduced to 22.7 pmol/L in nine patients with hereditary factor VII deficiency (factor VII coagulant activity less than 7%) but was not significantly different from normal controls in nine subjects with factor XI deficiency (factor XI coagulant activity less than 8%). These data indicate that factor IXa generation in vivo results mainly from the activity of the tissue factor mechanism rather than the contact system (factor XII, prekallikrein, high molecular-weight kininogen, factor XI). Our results may also help to explain the absence of a bleeding diathesis in many patients with deficiencies of the contact factors of coagulation.


1961 ◽  
Vol 10 (2) ◽  
pp. 157-180 ◽  
Author(s):  
Aldur W. Eriksson

SUMMARYAnother family in the Åland archipelago (Fennoscandia) suffering from a hemorrhagic disorder (von Willebrand-Jürgens' disease, heredi tary constitutional thrombopathie) is described. This family, so far the largest in the literature, has many common ancestors with the original bleeder families on Åland described in 1926 by v. Willebrand. Of the more than 1300 kindred traced genealogically, 132 (71 women and 61 men) in the five most recent generations have had manifest bleeding disorders in their medical history. Of the ca. 450 living relatives of this family 211 could be examined, and of these 56 females and 50 males were confirmed to be bleeders anamnestically, clinically or, and hematologically. Several cases were analysed exhaustively by modern coagulation tests. The clinical and laboratory hemostatic findings varied widely both inter- and intra-individually. Some patients showed a partial lack of a plasma factor (AHG) coupled with a qualitative platelet defect. Other patients of this family without bleeding disorders had a markedly prolonged bleeding time. The vascular disturbances also vary widely. The consanguinity in this pedigree is unusually high. The autosomal recessive in heritance are discussed. According to the mendelian segregation ratio, a not sex-linked, dominant transmission of the hemmorrhagic diathesis was in question. I has been possible to observe the hemostatic disturbances in 4-5 generations. The penetration of the gene is high, the expressiveness is unsteady.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1778-1778 ◽  
Author(s):  
Savita Rangarajan ◽  
Gary Moore ◽  
Tony Sunner ◽  
Katie Boast ◽  
Geoffrey Savidge

Abstract In the past many patients with inherited bleeding disorders contracted hepatitis C infection from the use of untreated plasma products leading to chronic liver disease. FVII, because of its short half-life has traditionally been used as a sensitive marker for subtle liver damage. In this study we measured Factors II, V, VII, X and XI in a cohort of 25 haemophilia patients who had longstanding hepatitis C infection in order to assess the effects of liver damage on these coagulation factors. The table below shows the number of patients with deficiencies of the measured factors together with the median levels in deficient patients. Also shown are the medians levels in cirrhotic and non cirrhotic patients. Frequencies of acquired factor deficiencies and median values Factor (Ref Range) FII (78–117)iu/dl FV (66–114)u/dl FVII (82–179)iu/dl FX (87–145)iu/dl FXI (76–136)u/dl Total patients = 25 Number of patients with deficiency 5/25 3/25 8/25 9/25 16/25 Median value in deficient patients(range) 52.6iu/dl (25.3–86.6)) 50.2u/dl (39.9–51.7) 60.6iu/dl (18.1–65.5) 73.5iu/dl (33.2–82) 52.2u/dl (20.5–68.9) Median value for cirrhotics(range) 52.6iu/dl (25.3–86.6) 51.7u/dl (39.9–76.3) 60iu/dl (18.1–65.5) 61.7iu/dl (33.2–73.5) 36.1u/dl (20.5–63.3) Median value for non cirrhotics(range) 89.6iu/dl (74.6–118.27) 118.2u/dl (84.9–174.3) 100.4iu/dl (49.5–150.3) 99.1iu/dl (78–146.8) 66.7u/dl (30.8–127) This data demonstrates that an acquired deficiency of FXI is much more common and severe than the other coagulation factors. 16 patients had low FXI levels compared to only 8 patients with low FVII. 5/25 patients had evidence of cirrhosis (median FVII-60iu/dl; median FXI-36.1u/dl). In the non-cirrhotic group, only 3 patients had low FVII compared to 11 patients with low FXI. 15/25 patients were non-cirrhotic with persistent hepatitis C viraemia (median FVII-100.4iu/dl; median FXI-66.7u/dl). 5/25 had cleared the hepatitis C virus after treatment with combination therapy with interferon and ribavarin with only one patient with persistently low FXI level (median FVII-112.9iu/dl; median XI-88.2u/dl). Our data suggests that low FXI levels have a greater discriminatory value for liver damage and possibly for liver regeneration after successful treatment for hepatitis C. This deficiency is a quantitative defect as the functional levels of FXI correlated with FXI antigen levels. Factor XI deficiency causes variable bleeding symptoms which are not predictable by the degree of deficiency. In contrast, deficiencies of Factors II, V, VII, X need to be severely reduced before bleeding symptoms are experienced. In the context of patients with inherited bleeding disorders the presence of an additional, acquired factor XI deficiency may have an impact on the severity of bleeding symptoms and patient management. This may be evidenced by breakthrough bleeding episodes on adequate prophylaxis or protracted resolution of a bleeding episode despite appropriate treatment with Factor VIII or IX concentrates. Increasing the dose of Factor VIII or IX concentrates may only partially resolve the bleeding episode but has significant impact on the cost of care for these patients. It is therefore crucial to be aware of the need to measure and monitor FXI levels in patients with haemophilia and hepatitis C. In these circumstances replacement of factor XI may need to be considered.


2011 ◽  
Vol 07 (01) ◽  
pp. 71
Author(s):  
Pär I Johansson ◽  
Sisse R Ostrowski ◽  
◽  

Recombinant activated factor VII ([rFVIIa] NovoSeven) was introduced in 1996 for the treatment of haemophilia patients with inhibitors (HPIs) to factor VIII or IX. This article reviews the evidence for the use of rFVIIa in congenital bleeding disorders. English-language databases were searched in September 2009 for reports of randomised controlled trials (RCTs) evaluating the effect of rFVIIa on haemostasis in congenital bleeding disorders. Eight RCTs comprising 256 HPIs were identified. The evidence for the use of rFVIIa in HPIs in terms of dose, clinical setting, modes of administration, efficacy and adverse events was weak, given the limited number of patients included and the heterogeneity of the RCTs. Overall, the haemostatic efficacy of rFVIIa varied from 25 to 100% in the studies reviewed; <1% of the patients receiving rFVIIa developed a thromboembolic adverse event. The authors suggest that the addition FVIIa therapy to HPIs should be based on the patient’s ability to generate thrombin and form a clot, rather than being based on weight alone. Assays reflecting thrombin generation, such as whole-blood thrombelastography, have the potential to significantly improve the treatment of these patients.


2019 ◽  
Vol 143 (2) ◽  
pp. 181-183
Author(s):  
Balraj Singh ◽  
Varun Modi ◽  
Parminder Kaur ◽  
Gunwant Guron ◽  
Michael Maroules

Thrombotic events in bleeding disorders such as hemophilia A or B, Von Willebrand disease, afibrinogenemia, factor VII deficiency, and factor XI deficiency are rare but have been reported. These events usually occur in the presence of prothrombotic risk factors such as recent surgery, trauma, or factor replacement therapy. We present a case of a 68-year-old Hispanic female with a history of factor VII deficiency who presented with shortness of breath, chest pain, and palpitations and was found to have pulmonary embolism. Our patient did not have any of the above-mentioned thrombotic risk factors. Our case and review of the literature show that factor VII deficiency does not provide protection against thrombosis.


2009 ◽  
Vol 101 (06) ◽  
pp. 1104-1111 ◽  
Author(s):  
Claudia Chi ◽  
Christine Lee ◽  
Adrian England ◽  
Jaishree Hingorani ◽  
James Paintsil ◽  
...  

SummaryA retrospective review was carried out on the methods of obstetric analgesia/anesthesia used in 80 pregnancies amongst 63 women with inherited bleeding disorders (19 factor XI deficiency, 16 carriers of haemophilia, 15 von Willebrand disease, seven platelet function disorders, four factor VII deficiency, one factor VII and XI deficiency and one factor X deficiency). In 72 pregnancies, the woman was seen antenatally in a multidisciplinary clinic to discuss and plan pain relief options. Regional block was performed for 41 pregnancies. The mothers were known to have a bleeding disorder in 35 of these pregnancies. Prophylactic cover was given in 10 pregnancies prior to the insertion of regional block but not required in the remaining 25 pregnancies because the coagulation defects had spontaneously normalised at term. There were six reported adverse effects from regional block similar to that found in the general population: inadequate anesthesia/analgesia (2), bloody tap (2), hypotension and a possible dural puncture which was treated conservatively. There were no reports of long-term complications. The findings show that it is possible to offer women with inherited bleeding disorders the option of regional block provided their coagulation defects have normalised, either spontaneously during pregnancy or following adequate haemostatic cover.


Sign in / Sign up

Export Citation Format

Share Document